Risk of systemic adverse events after botulinum neurotoxin A treatment in cerebral palsy
Dev Med Child Neurol
.
2018 Nov;60(11):1074.
doi: 10.1111/dmcn.14025.
Epub 2018 Aug 31.
Author
Antigone S Papavasiliou
1
Affiliation
1
IASO Children's Hospital - Paediatric Neurology, Athens, Greece.
PMID:
30171611
DOI:
10.1111/dmcn.14025
No abstract available
Publication types
Comment
MeSH terms
Botulinum Toxins
Botulinum Toxins, Type A*
Cerebral Palsy*
Humans
Muscle Spasticity
Neuromuscular Agents
Risk
Substances
Neuromuscular Agents
Botulinum Toxins
Botulinum Toxins, Type A